Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Tumor microRNA-126 controls cell viability and associates with poor survival in patients with esophageal adenocarcinoma.

Toxopeus E, Lynam-Lennon N, Biermann K, Dickens G, de Ruiter PE, van Lanschot J, Reynolds JV, Wijnhoven B, O'Sullivan J, van der Laan L.

Exp Biol Med (Maywood). 2019 Oct;244(14):1210-1219. doi: 10.1177/1535370219868671. Epub 2019 Aug 7. No abstract available.

PMID:
31390899
2.

Visceral Adipose Tissue Modulates Radiosensitivity in Oesophageal Adenocarcinoma.

Mongan AM, Lynam-Lennon N, Doyle SL, Casey R, Carr E, Cannon A, Conroy MJ, Pidgeon GP, Brennan L, Lysaght J, Reynolds JV, O'Sullivan J.

Int J Med Sci. 2019 Apr 5;16(4):519-528. doi: 10.7150/ijms.29296. eCollection 2019.

3.

Pyrazinib (P3), [(E)-2-(2-Pyrazin-2-yl-vinyl)-phenol], a small molecule pyrazine compound enhances radiosensitivity in oesophageal adenocarcinoma.

Buckley AM, Dunne MR, Lynam-Lennon N, Kennedy SA, Cannon A, Reynolds AL, Maher SG, Reynolds JV, Kennedy BN, O'Sullivan J.

Cancer Lett. 2019 Apr 10;447:115-129. doi: 10.1016/j.canlet.2019.01.009. Epub 2019 Jan 19.

PMID:
30664962
4.

Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma.

Buckley AM, Lynam-Lennon N, Kennedy SA, Dunne MR, Aird JJ, Foley EK, Clarke N, Ravi N, O'Toole D, Reynolds JV, Kennedy BN, O'Sullivan J.

Oncotarget. 2018 Sep 14;9(72):33634-33647. doi: 10.18632/oncotarget.25950. eCollection 2018 Sep 14.

5.

Advances in Precision Medicine: Tailoring Individualized Therapies.

Matchett KB, Lynam-Lennon N, Watson RW, Brown JAL.

Cancers (Basel). 2017 Oct 25;9(11). pii: E146. doi: 10.3390/cancers9110146.

6.

MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype.

Lynam-Lennon N, Heavey S, Sommerville G, Bibby BA, Ffrench B, Quinn J, Gasch C, O'Leary JJ, Gallagher MF, Reynolds JV, Maher SG.

Oncotarget. 2017 Feb 14;8(7):11400-11413. doi: 10.18632/oncotarget.13940.

7.

Big Data-Led Cancer Research, Application, and Insights.

Brown JA, Ni Chonghaile T, Matchett KB, Lynam-Lennon N, Kiely PA.

Cancer Res. 2016 Nov 1;76(21):6167-6170. Epub 2016 Oct 20.

8.

Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells.

McDermott N, Meunier A, Mooney B, Nortey G, Hernandez C, Hurley S, Lynam-Lennon N, Barsoom SH, Bowman KJ, Marples B, Jones GD, Marignol L.

Sci Rep. 2016 Oct 5;6:34796. doi: 10.1038/srep34796.

9.

Changes in mitochondrial stability during the progression of the Barrett's esophagus disease sequence.

O'Farrell NJ, Feighery R, Picardo SL, Lynam-Lennon N, Biniecka M, McGarrigle SA, Phelan JJ, MacCarthy F, O'Toole D, Fox EJ, Ravi N, Reynolds JV, O'Sullivan J.

BMC Cancer. 2016 Jul 19;16:497. doi: 10.1186/s12885-016-2544-2.

10.

Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma.

Lynam-Lennon N, Bibby BA, Mongan AM, Marignol L, Paxton CN, Geiersbach K, Bronner MP, O'Sullivan J, Reynolds J, Maher SG.

Mol Med. 2016 May 23;22. doi: 10.2119/molmed.2016.00020.

11.

Erratum to: Visceral obesity stimulates anaphase bridge formation and spindle assembly checkpoint dysregulation in radioresistant oesophageal adenocarcinoma.

Mongan AM, Lynam-Lennon N, Casey R, Maher S, Pidgeon G, Reynolds JV, O'Sullivan J.

Clin Transl Oncol. 2016 Jun;18(6):651. No abstract available.

PMID:
26590054
12.

Visceral obesity stimulates anaphase bridge formation and spindle assembly checkpoint dysregulation in radioresistant oesophageal adenocarcinoma.

Mongan AM, Lynam-Lennon N, Casey R, Maher S, Pidgeon G, Reynolds JV, O'Sullivan J.

Clin Transl Oncol. 2016 Jun;18(6):632-40. doi: 10.1007/s12094-015-1411-y. Epub 2015 Oct 16. Erratum in: Clin Transl Oncol. 2016 Jun;18(6):651.

PMID:
26474871
13.

Excess visceral adiposity induces alterations in mitochondrial function and energy metabolism in esophageal adenocarcinoma.

Lynam-Lennon N, Connaughton R, Carr E, Mongan AM, O'Farrell NJ, Porter RK, Brennan L, Pidgeon GP, Lysaght J, Reynolds JV, O'Sullivan J.

BMC Cancer. 2014 Dec 3;14:907. doi: 10.1186/1471-2407-14-907.

14.

Differential expression of mitochondrial energy metabolism profiles across the metaplasia-dysplasia-adenocarcinoma disease sequence in Barrett's oesophagus.

Phelan JJ, MacCarthy F, Feighery R, O'Farrell NJ, Lynam-Lennon N, Doyle B, O'Toole D, Ravi N, Reynolds JV, O'Sullivan J.

Cancer Lett. 2014 Nov 1;354(1):122-31. doi: 10.1016/j.canlet.2014.07.035. Epub 2014 Aug 10.

PMID:
25107643
15.

Altered mitochondrial function and energy metabolism is associated with a radioresistant phenotype in oesophageal adenocarcinoma.

Lynam-Lennon N, Maher SG, Maguire A, Phelan J, Muldoon C, Reynolds JV, O'Sullivan J.

PLoS One. 2014 Jun 26;9(6):e100738. doi: 10.1371/journal.pone.0100738. eCollection 2014.

16.

MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma.

Lynam-Lennon N, Reynolds JV, Marignol L, Sheils OM, Pidgeon GP, Maher SG.

J Mol Med (Berl). 2012 Dec;90(12):1449-58. doi: 10.1007/s00109-012-0924-x. Epub 2012 Jun 17.

PMID:
22706599
17.

Identification of a mutation in LARS as a novel cause of infantile hepatopathy.

Casey JP, McGettigan P, Lynam-Lennon N, McDermott M, Regan R, Conroy J, Bourke B, O'Sullivan J, Crushell E, Lynch S, Ennis S.

Mol Genet Metab. 2012 Jul;106(3):351-8. doi: 10.1016/j.ymgme.2012.04.017. Epub 2012 Apr 26.

PMID:
22607940
18.

Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma.

Lynam-Lennon N, Reynolds JV, Pidgeon GP, Lysaght J, Marignol L, Maher SG.

Radiat Res. 2010 Dec;174(6):703-11. doi: 10.1667/RR2295.1. Epub 2010 Oct 4.

PMID:
21128793
19.

The roles of microRNA in cancer and apoptosis.

Lynam-Lennon N, Maher SG, Reynolds JV.

Biol Rev Camb Philos Soc. 2009 Feb;84(1):55-71. doi: 10.1111/j.1469-185X.2008.00061.x. Epub 2008 Nov 22. Review.

PMID:
19046400

Supplemental Content

Loading ...
Support Center